

Prior Authorization Request Form for Migraine Prevention Agent

FAX this completed form to (844) 205-3386

OR Mail requests to: Pharmacy Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720 OR Prior authorization may be completed at https://www.covermymeds.com/main/prior-authorization-forms/

I. PROVIDER INFORMATION		II. MEMBER INFO	RMATION
Prescriber Name:		Member Name:	
Prescriber Specialty:		Identification #:	
NPI:		Group #:	
Office Contact Name:		Date of Birth:	
Fax #:		Medication Allergies:	
Phone #:			
III. DRUG INFORMATION (One drug	request per form	ı)	
Drug name and strength:	Dosage Interval (sig	g):	Qty. per Day:
IV. REQUIRED DOCUMENTION (Detaitem must be submitted with prior a			demonstrating evidence for each
Specify diagnosis & diagnosis code releva	nt to this request:	Dx/Dx Code:	
Does the member have a history of contra medication?	aindication to the pre	escribed	
but the United Council for Neurolo consulted: Will discontinue use of Migraine P Has a medical reason for concominational treatment gu For a gepant, if using a different ge Will discontinue use of the gepant	ontraindication or into onts? Refer to a list of preferred and owing specialist neurogical Subspecialties or	olerance Yes d non- No rologist or headache s (UCNS)), please indice or to starting the requested gepant nts that is supported has a documented his monoclonal antibodic t and end date): lefer to https://www.	by peer-reviewed literature or national story of therapeutic failure, es (mAbs) approved or medically adhs.pa.gov/providers/Pharmacy-
Society Classification of Headache Average number of migraine and l Member has 4 or more migraine d	ne with or without au Disorder headache days per m lays per month over t c failure, contraindic	ura confirmed accord onth at baseline the past 3 months eation or intolerance t	ing to the current International Headache that prohibits a trial of at least 1 from two of

Beta-Blocker (e.g. metoprolol, propranolol, timo	-				
Antidepressant (e.g. amitriptyline, venlafaxine):Anticonvulsant (e.g. topiramate, valproic acid, divalproex):					
MIGRAINE PREVENTION RENEWAL REQUESTS:					
Member has had a reduction in the average number of migraine and headache days per month from baseline					
☐ Member has experienced a decrease in severity or du					
by:					
EPISODIC CLUSTER HEADACHE:					
☐ Member has a diagnosis of episodic cluster headache Society Classification of Headache Disorder	confirmed according to the current Interna	tional Headache			
 □ Documented history of therapeutic failure, contraindi recommended by consensus guidelines for episodic cl Academy of Family Physicians, American Headache Sc □ Verapamil: □ Topiramate: 	uster headache (American Academy of Netociety): (medication, start date and end dat	ırology, American			
EPISODIC CLUSTER HEADACHE RENEWAL REQUESTS:					
Member has experienced a positive clinical response a baseline	as evident by a reduction in cluster headac	he frequency from			
IV. ADDITIONAL RATIONALE FOR REQUEST / PERTI	NENT CLINICAL INFORMATION:				
Appropriate clinical information to support the request on the basis of medical necessity must be submitted.	Provider Signature:	Date:			
	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·			

Pharmacy Department will respond via fax or phone within 24 hours.

Requests for prior authorization (PA) requests must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)